<p>Atossa Therapeutics, Inc.（纳斯达克代码：ATOS - 获取免费报告）在 12 月份的空头头寸显著下降。截至 12 月 15 日，空头头寸总计为 8,200,000 股，较 11 月 30 日的 11,600,000 股下降了 29.3%。根据 705,500 股的平均日交易量，目前的空头头寸比率为 11.6 天。</p>
<p>获取 <strong>Atossa Therapeutics</strong> 警报：</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 ATOS 股票发表了评论。HC Wainwright 在 12 月 12 日的报告中重申了对 Atossa Therapeutics 的 “买入” 评级，并给出了 7.00 美元的目标价。Ascendiant Capital Markets 在 12 月 9 日的报告中将 Atossa Therapeutics 的目标价从 6.50 美元上调至 7.00 美元，并给予该公司 “买入” 评级。最后，StockNews.com 在 11 月 18 日的研究报告中将 Atossa Therapeutics 的评级从 “持有” 下调至 “卖出”。</p>
<p><strong>获取我们关于 ATOS 的最新报告</strong></p>
<h2>Atossa Therapeutics 股票下跌 7.4%</h2>
<p>Atossa Therapeutics 的股票在周五开盘价为 0.98 美元。该公司的市值为 1.2342 亿美元，市盈率为-4.46，贝塔系数为 1.21。Atossa Therapeutics 的 52 周低点为 0.77 美元，52 周高点为 2.31 美元。该公司的 50 日简单移动平均线为 1.27 美元，200 日简单移动平均线为 1.31 美元。</p>
<h2>Atossa Therapeutics 的机构交易</h2>
<p>一些机构投资者最近调整了他们对 ATOS 的持股。XTX Topco Ltd 在第二季度收购了 Atossa Therapeutics 的新股份，价值约 29,000 美元。Intech Investment Management LLC 在第三季度购买了 Atossa Therapeutics 的新头寸，价值约 29,000 美元。SG Americas Securities LLC 在第三季度将其在 Atossa Therapeutics 的持股增加了 254.3%。SG Americas Securities LLC 目前拥有 41,849 股该公司的股票，价值 64,000 美元，在此期间又购买了 30,037 股。制造商人寿保险公司在第三季度购买了 Atossa Therapeutics 的新头寸，价值约 75,000 美元。最后，Rhumbline Advisers 在第二季度收购了 Atossa Therapeutics 的新头寸，价值约 161,000 美元。目前 12.74% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Atossa Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Atossa Therapeutics, Inc.是一家临床阶段的生物制药公司，开发针对女性乳腺癌及其他疾病的未满足医疗需求的药物。该公司的主要药物候选者是口服（Z）- 恩多昔芬，作为他莫昔芬的活性代谢物，目前正在进行 II 期临床试验，以治疗和预防乳腺癌。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Atossa Therapeutics</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>巴菲特上钩；伯克希尔在 12 月增持 Oxy</li>
<li>投资汽车股票</li>
<li>2025 年对抗通胀的三大 ETF</li>
<li>上海证券交易所综合指数是什么？</li>
<li>这三只芯片股票仍然是 2025 年的买入</li>
</ul>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<p>→ 30 年市场现象开启过夜机会（来自 ProsperityPub）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg5Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg5Ng"/></p>
<h2>你现在应该投资 1,000 美元在 Atossa Therapeutics 吗？</h2>
<p>在你考虑 Atossa Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Atossa Therapeutics 并不在名单上。</p>
<p>虽然 Atossa Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ATOS

<p>Atossa Therapeutics, Inc.（纳斯达克代码：ATOS）在 12 月份的空头头寸显著下降 29.3%，从 11 月份的 11,600,000 股降至 8,200,000 股。目前的空头头寸比率为 11.6 天，基于平均每日交易量 705,500 股。分析师们的看法不一，HC Wainwright 和 Ascendiant Capital 维持 “买入” 评级，目标价为 7.00 美元，而 StockNews.com 则将该股票下调至 “卖出”。Atossa 的股票开盘价为 0.98 美元，市值为 1.2342 亿美元，市盈率为-4.46</p>

<p>Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a decline of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily trading volume, of 705,500 shares, the short-interest ratio is presently 11.6 days.</p>
<div class="lb-trans"><p>Atossa Therapeutics, Inc.（纳斯达克代码：ATOS - 获取免费报告）在 12 月份的空头头寸显著下降。截至 12 月 15 日，空头头寸总计为 8,200,000 股，较 11 月 30 日的 11,600,000 股下降了 29.3%。根据 705,500 股的平均日交易量，目前的空头头寸比率为 11.6 天。</p>
</div><p>Get <strong>Atossa Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Atossa Therapeutics</strong> 警报：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently commented on ATOS shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, December 12th. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Monday, December 9th. Finally, StockNews.com downgraded Atossa Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Monday, November 18th.</p>
<div class="lb-trans"><p>一些股票分析师最近对 ATOS 股票发表了评论。HC Wainwright 在 12 月 12 日的报告中重申了对 Atossa Therapeutics 的 “买入” 评级，并给出了 7.00 美元的目标价。Ascendiant Capital Markets 在 12 月 9 日的报告中将 Atossa Therapeutics 的目标价从 6.50 美元上调至 7.00 美元，并给予该公司 “买入” 评级。最后，StockNews.com 在 11 月 18 日的研究报告中将 Atossa Therapeutics 的评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Get Our Latest Report on ATOS</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ATOS 的最新报告</strong></p>
</div><h2>Atossa Therapeutics Stock Down 7.4 %</h2>
<div class="lb-trans"><h2>Atossa Therapeutics 股票下跌 7.4%</h2>
</div><p>Shares of Atossa Therapeutics stock opened at $0.98 on Friday. The firm has a market cap of $123.42 million, a price-to-earnings ratio of -4.46 and a beta of 1.21. Atossa Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.31. The company's 50-day simple moving average is $1.27 and its 200-day simple moving average is $1.31.</p>
<div class="lb-trans"><p>Atossa Therapeutics 的股票在周五开盘价为 0.98 美元。该公司的市值为 1.2342 亿美元，市盈率为-4.46，贝塔系数为 1.21。Atossa Therapeutics 的 52 周低点为 0.77 美元，52 周高点为 2.31 美元。该公司的 50 日简单移动平均线为 1.27 美元，200 日简单移动平均线为 1.31 美元。</p>
</div><h2>Institutional Trading of Atossa Therapeutics</h2>
<div class="lb-trans"><h2>Atossa Therapeutics 的机构交易</h2>
</div><p>A number of institutional investors have recently modified their holdings of ATOS. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth about $29,000. Intech Investment Management LLC purchased a new position in shares of Atossa Therapeutics in the 3rd quarter worth about $29,000. SG Americas Securities LLC grew its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Atossa Therapeutics in the third quarter valued at about $75,000. Finally, Rhumbline Advisers acquired a new position in shares of Atossa Therapeutics during the second quarter worth about $161,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了他们对 ATOS 的持股。XTX Topco Ltd 在第二季度收购了 Atossa Therapeutics 的新股份，价值约 29,000 美元。Intech Investment Management LLC 在第三季度购买了 Atossa Therapeutics 的新头寸，价值约 29,000 美元。SG Americas Securities LLC 在第三季度将其在 Atossa Therapeutics 的持股增加了 254.3%。SG Americas Securities LLC 目前拥有 41,849 股该公司的股票，价值 64,000 美元，在此期间又购买了 30,037 股。制造商人寿保险公司在第三季度购买了 Atossa Therapeutics 的新头寸，价值约 75,000 美元。最后，Rhumbline Advisers 在第二季度收购了 Atossa Therapeutics 的新头寸，价值约 161,000 美元。目前 12.74% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Atossa Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Atossa Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.</p>
<div class="lb-trans"><p>Atossa Therapeutics, Inc.是一家临床阶段的生物制药公司，开发针对女性乳腺癌及其他疾病的未满足医疗需求的药物。该公司的主要药物候选者是口服（Z）- 恩多昔芬，作为他莫昔芬的活性代谢物，目前正在进行 II 期临床试验，以治疗和预防乳腺癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Atossa Therapeutics</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Buffett Takes the Bait; Berkshire Buys More Oxy in December</li>
<li>Investing In Automotive Stocks</li>
<li>Top 3 ETFs to Hedge Against Inflation in 2025</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>These 3 Chip Stock Kings Are Still Buys for 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Atossa Therapeutics</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>巴菲特上钩；伯克希尔在 12 月增持 Oxy</li>
<li>投资汽车股票</li>
<li>2025 年对抗通胀的三大 ETF</li>
<li>上海证券交易所综合指数是什么？</li>
<li>这三只芯片股票仍然是 2025 年的买入</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><p>→ 30-year market phenomenon opens up overnight opportunity (From ProsperityPub)(Ad)</p>
<div class="lb-trans"><p>→ 30 年市场现象开启过夜机会（来自 ProsperityPub）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg5Ng" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10896&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Atossa Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Atossa Therapeutics 吗？</h2>
</div><p>Before you consider Atossa Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Atossa Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Atossa Therapeutics 并不在名单上。</p>
</div><p>While Atossa Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Atossa Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Atossa Therapeutics, Inc.（纳斯达克股票代码：ATOS）的空头头寸大幅减少